The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Predictive factors for the efficacy of nal-IRI + 5FU/LV therapy in patients previously treated with conventional irinotecan.
 
Yasutsugu Asai
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Incyte (Inst); Lilly (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Satoshi Kobayashi
Honoraria - AstraZeneca; Bayer Yakuhin; Chugai Pharma; Eisai; Lilly; MSD; Otsuka; Taiho Pharmaceutical; Takeda; Yakult Honsha; Zymeworks
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Eisai (Inst); Incyte (Inst); Lilly (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Kazumasa Shiraishi
No Relationships to Disclose
 
Masato Enomoto
No Relationships to Disclose
 
Tomomi Hamaguchi
No Relationships to Disclose
 
Yuichiro Tozuka
No Relationships to Disclose
 
Taito Fukushima
Honoraria - AstraZeneca; Chugai Pharma; Eisai; Takeda
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); MSD (Inst); SERVIER (Inst)
 
Shun Tezuka
No Relationships to Disclose
 
Makoto Ueno
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Incyte; J-pharma; MSD; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chiome Bioscience (Inst); Chiome Bioscience (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); Incyte (Inst); J-pharma (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Junji Furuse
Honoraria - Astellas Pharma; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Incyte Japan; J-Pharma; MSD; Novartis; Ohara Pharmaceutical; Pfizer; SERVIER; Taiho Pharmaceutical; Takeda; Teijin Pharma
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Delta-Fly Pharma; Eisai; J-Pharma; MSD; OncoTherapy Science